Saturday August 19th 2017

Biogen’s Tecfidera approved in Europe, first launch expected in Germany

Biogen Idec has received approval to launch its soon-to-be blockbuster multiple sclerosis drug, Tecfidera, in Europe, and plans to begin with a launch in Germany in the coming weeks. Approval was widely expected after a committee of the European Medicines Agency voted in favor of the oral pill last November, but the launch was delayed as the Cambridge, Mass.-based company sought 10 extra years of protection there before generic versions of the drug would be allowed. Besides U.S. approval last March,… (Source: bizjournals.com Health Care:Biotechnology headlines)

Read article here: 

Biogen’s Tecfidera approved in Europe, first launch expected in Germany

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]

Drug blocked by regulators found to improve quality of life for MS patients
Drug blocked by regulators found to improve quality of life for MS patients

A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with [Read More]

House Dems launch MS drug pricing probe
House Dems launch MS drug pricing probe

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of [Read More]